Skip to content
buyModerate

David Scott Moore bought $250k of CRVS

director at Corvus Pharmaceuticals, Inc.. 21,700 shares at an average of $11.53, traded Jun 11, 2026, filed Jun 15, 2026.

Conviction score
44
Value
$250k
21,700 shares
Holdings after
21,700
change unknown
From 52-week low
+211%
low $3.73, close $11.60
From 52-week high
-55%
high $25.52, as of Jun 11, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $250k at market
    +13
  • Relative to holdings
    First purchase: no shares before this trade
    +8
  • Price context
    55% below the 52-week high
    +8
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CRVSOct 13, 2026 · close 9.41
Since filing Jun 15, 2026: -20.9%SPY +3.6% · excess -24.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001610717-26-000223, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 11, 2026POpen-market purchase
Common Stock
+21,700$11.53$250k21,700Jun 15, 2026
Jun 11, 2026AGrant or award
Stock Option (Right to Buy)derivative
+15,000$0.00$015,000Jun 15, 2026

Related signals

Other insiders at Corvus Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
37Weak
CRVSbuy
Corvus Pharmaceuticals, Inc.
Richard A Miller Md
President and CEO
$83k
6,932 shares
+1%
53Moderate
CRVSsell 2
Corvus Pharmaceuticals, Inc.
Peter A. Thompson
director, owner
$4.9M
1,176,332 shares
-14%
53Moderate
CRVSsell 2
Corvus Pharmaceuticals, Inc.
Orbimed Advisors LLC
director, owner
$4.9M
1,176,332 shares
-14%
74Notable
CRVSbuy 2
Corvus Pharmaceuticals, Inc.
Richard A Miller Md
President and CEO
$1000k
577,634 shares
-
40Moderate
CRVSbuy 2
Corvus Pharmaceuticals, Inc.
William Benton Jones
See Remarks
$35k
20,000 shares
+15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David Scott Moore bought $250k of CRVS | InsiderTell